Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma
2
Issued Date
2024-03-01
Resource Type
ISSN
02507005
eISSN
17917530
Scopus ID
2-s2.0-85186337401
Pubmed ID
38423667
Journal Title
Anticancer Research
Volume
44
Issue
3
Start Page
1023
End Page
1031
Rights Holder(s)
SCOPUS
Bibliographic Citation
Anticancer Research Vol.44 No.3 (2024) , 1023-1031
Suggested Citation
Cheevapruk K., Ueno M., Sungwan P., Sittithumcharee G., Kariya R., Sampattavanich S., Okada S. Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma. Anticancer Research Vol.44 No.3 (2024) , 1023-1031. 1031. doi:10.21873/anticanres.16897 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/97558
Title
Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma
Corresponding Author(s)
Other Contributor(s)
Abstract
Background/Aim: Multiple myeloma (MM), the second most common hematological malignancy, is characterized by the accumulation of malignant plasma cells within the bone marrow. Despite various drug classes for MM treatment, it remains incurable, necessitating novel and efficacious agents. This study aims to explore the anti-cancer activity of a midkine inhibitor, iMDK (C21H13FN2O2S), in myeloma cell lines. Materials and Methods: This study assessed the antiproliferative activity using the MTT assay. Cell cycle and apoptosis were evaluated using flow cytometry. To further investigate the inhibitory mechanism, western blotting was used to detect cell cycle-related proteins, pro-apoptotic proteins, and anti-apoptotic proteins. Results: iMDK inhibits MM cell proliferation in a dose- and time-dependent manner, inducing cell cycle arrest and apoptosis. The reduction in Cdc20 expression by iMDK treatment leads to G2/M phase cell cycle arrest. Furthermore, iMDK down-regulates anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1, and c-FLIP), thereby activating both intrinsic and extrinsic apoptosis pathways. Conclusion: iMDK could be a potential candidate for MM treatment.